PHOENIX, Feb. 4 /PRNewswire/ -- Cancer is the second leading cause of death with over 6 million new cases worldwide each year. In the U.S. alone, one million new cases of cancer are diagnosed annually, and half a million Americans lose their battle with the disease every year. Now, following years of research, GlycoMeds (http://www.cancer-test-kits.com) has released the first early detection system for whole-body cancers.
What was needed was a way to detect it in the early stages when it’s easiest to treat. The medical establishment has long sought just such a tool -- a reliable, simple test that catches cancer in its early stages. While a few companies have designed tests for specific cancers, those tests require the cancer to be present. What’s more, these tests are limited to only a few specific types of cancer.
In contrast, the GlycoMeds patent-pending Cancer Test (http://www.cancer-test-kits.com/articlesCancerMarketTest.htm) is a broad-scope test that detects conditions within the body that allow cancer cell growth prior to cancer cells being active. Employing a test process that produces consistent measurements of the chemical composition of a person’s saliva, GlycoMeds’ Cancer Test Kit is an inexpensive, at-home test that can alert the user to the presence of conditions within their body that are conducive to the growth of 74% of all cancers (including breast, lung, kidney, colon, liver, bone and brain cancer). The Cancer Test Kit does not measure pH.
“The new Cancer Test is not keyed for any specific cancer,” explained Dr. Roger Brown, CEO of GlycoMeds. “The test is more sensitive to whole-body type of cancers rather than small, localized malignant tumors which don’t generally disrupt the body’s entire system.”
The GlycoMeds Cancer Test works because most cancer cells live in a narrow pH range within the body. As long as the body’s system pH is outside that range, most cancer cells cannot survive. The GlycoMeds test measures the changes in a person’s fluidic system once a day for three days, averages those changes, and compares them to the changes a healthy person’s fluidic system would undergo. The measurement is then equated to a condition level on a scale of 0 to 7, where 0 is healthy -- no conditions conducive to the growth of whole-body cancer cells -- and 7 has a prognosis of death.
If the level number reveals an active possibility of cancer (levels 4, 5 or 6), the person taking the test is advised to make an appointment with his or her doctor for further evaluation. But if the test shows cancer is not imminent (levels 1, 2 or 3), the person taking the test can take corrective action to bring his or her system back to normal, thus inhibiting cancer cell growth.
GlycoMeds is now seeking a partner to license and market their Cancer Test Kit, which has not yet been presented to the FDA for comment. To learn more, visit http://www.cancer-test-kits.com/articlesCancerMarketTest.htm.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
CONTACT: Roger Brown, Ph.D., of GlycoMeds, +1-602-441-4225,
rbrown@vreh.com
Web site: http://www.cancer-test-kits.com/
